Trials / Completed
CompletedNCT04306302
A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults
A Randomized, Double-blind, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Doses of VAC52416 (ExPEC10V) in Japanese Adults Aged 60 to 85 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and reactogenicity of different doses of extraintestinal pathogenic Escherichia coli 10 valent (ExPEC10V) in Japanese participants greater than or equal to (\>=) 60 to less than or equal to (\<=) 85 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ExPEC10V | Participants will receive a single IM injection of ExPEC10V. |
| BIOLOGICAL | Placebo | Participants will receive single IM injection of matching placebo. |
Timeline
- Start date
- 2020-03-13
- Primary completion
- 2020-12-24
- Completion
- 2020-12-24
- First posted
- 2020-03-12
- Last updated
- 2021-01-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04306302. Inclusion in this directory is not an endorsement.